Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone

Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides t...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 86; no. 16; pp. 6313 - 6317
Main Authors Bajusz, S., Janaky, T., Csernus, V. J., Bokser, L., Fekete, M., Srkalovic, G., Redding, T. W., Schally, A. V.
Format Journal Article
LanguageEnglish
Published Washington, DC National Academy of Sciences of the United States of America 01.08.1989
National Acad Sciences
Subjects
LH
Online AccessGet full text

Cover

Loading…
Abstract Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N-ε(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1, D-Phe(pCl)2,D-Pal(3)2, Arg5, D-Lys{Dl-A2pr(Sal2Cu)}$^{6}$ , D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(Dl-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μ g in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.
AbstractList Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.
Metal complexes related to the cytotoxic complexes cisplatin (cis-diamminedichloroplatinum(II)) and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer and prostate cancer cell lines in vitro. Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.
Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N epsilon-(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1,D-Phe(pCl)2, D-Pal(3)2, Arg5,D-Lys[DL-A2pr(Sal2Cu)]6,D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(DL-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 micrograms in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.
Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated into suitably modified luteinizing hormone-releasing hormone (LH-RH) analogues containing D-lysine at position 6. Some of the metallopeptides thus obtained proved to be highly active LH-RH agonists or antagonists. For instance, SB-40, a PtCl2-containing metallopeptide in which platinum is coordinated to an N-ε(DL-2,3-diaminopropionyl)-D-lysine residue [D-Lys(DL-A2pr] at position 6, showed 50 times higher LH-releasing potency than the native hormone. SB-95, [Ac-D-Nal(2)1, D-Phe(pCl)2,D-Pal(3)2, Arg5, D-Lys{Dl-A2pr(Sal2Cu)}$^{6}$ , D-Ala10]LH-RH, where Nal(2) is 3-(2-naphthyl)alanine, Pal(3) is 3-(3-pyridyl)alanine, and copper(II) is coordinated to the salicylideneimino moieties resulting from condensation of salicylaldehyde with D-Lys(Dl-A2pr)6, caused 100% inhibition of ovulation at a dose of 3 μ g in rats. Most metallopeptide analogues of LH-RH showed high affinities for the membrane receptors of rat pituitary and human breast cancer cells. Some of these metallopeptides had cytotoxic activity against human breast cancer and prostate cancer cell lines in vitro (this will be the subject of a separate paper on cytotoxicity evaluation). Such cytostatic metallopeptides could be envisioned as targeted chemotherapeutic agents in cancers that contain receptors for LH-RH-like peptides.
Author Schally, A. V.
Bokser, L.
Fekete, M.
Redding, T. W.
Srkalovic, G.
Csernus, V. J.
Bajusz, S.
Janaky, T.
AuthorAffiliation Endocrine Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA
AuthorAffiliation_xml – name: Endocrine Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA
Author_xml – sequence: 1
  givenname: S.
  surname: Bajusz
  fullname: Bajusz, S.
– sequence: 2
  givenname: T.
  surname: Janaky
  fullname: Janaky, T.
– sequence: 3
  givenname: V. J.
  surname: Csernus
  fullname: Csernus, V. J.
– sequence: 4
  givenname: L.
  surname: Bokser
  fullname: Bokser, L.
– sequence: 5
  givenname: M.
  surname: Fekete
  fullname: Fekete, M.
– sequence: 6
  givenname: G.
  surname: Srkalovic
  fullname: Srkalovic, G.
– sequence: 7
  givenname: T. W.
  surname: Redding
  fullname: Redding, T. W.
– sequence: 8
  givenname: A. V.
  surname: Schally
  fullname: Schally, A. V.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19510858$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/2548206$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/7191552$$D View this record in Osti.gov
BookMark eNp9kcFrFDEYxYNU6rZ6FgRlKKin2SaTTCY5eChFXWGlInoOafbLbko2GScZsf3rzbDr0gp6CuT93peX952goxADIPSc4DnBHT3vg05zweeEzzkl9BGaESxJzZnER2iGcdPVgjXsCTpJ6QZjLFuBj9Fx0zLRYD5DVwu33vjb6kvMEHL1GbL2PvbQZ7eC6iJoH9cjpCraajlmcMHdubCuFnHYliD1V_Cg072bp-ix1T7Bs_15ir5_eP_tclEvrz5-urxY1qYlItcrSiU3oHnTWsKg1RKoJYJfS06MZNAxCoSC4MAk0dDZztqSmXR4JRumMT1F73Zz-_F6CytTwg_aq35wWz3cqqideqgEt1Hr-FM1shONLP6znT-m7FQyLoPZmBgCmKw6IknbNgV6s39kiD9KC1ltXTLgvQ4Qx6S6gpW6aQFf3k9ziLGvueiv97pORns76GBcOmBEljGiFYVrd5wZYkoDWFWC6ezi9AfnFcFq2rqatq4EV4SraevFd_6X7zD6n45X-0ST8Id-ALz9L6Ds6H2GX7mQL3bkTcpxOKCUUSLob14u0To
CODEN PNASA6
CitedBy_id crossref_primary_10_1002_anie_201204631
crossref_primary_10_1007_s00726_010_0766_1
crossref_primary_10_1016_S1016_8478_23_13504_7
crossref_primary_10_1016_j_brainresbull_2015_11_002
crossref_primary_10_1562_0031_8655_2001_0740226GOFRBE2_0_CO2
crossref_primary_10_1016_j_ctrv_2012_12_003
crossref_primary_10_1016_j_jconrel_2016_11_002
crossref_primary_10_1016_S0163_7258_99_00018_2
crossref_primary_10_1007_s43393_021_00037_9
crossref_primary_10_1002_med_20225
crossref_primary_10_1111_j_1600_0897_2005_00350_x
crossref_primary_10_1002_pros_2990230209
crossref_primary_10_1002_psc_2769
crossref_primary_10_3762_bjoc_14_226
crossref_primary_10_1007_BF01961247
crossref_primary_10_1002_pros_10259
crossref_primary_10_1007_BF01806208
crossref_primary_10_1007_BF02443499
crossref_primary_10_1007_BF00127660
crossref_primary_10_1002_zaac_19976230194
crossref_primary_10_1002_ange_201204631
crossref_primary_10_1002_pros_2990260403
crossref_primary_10_1002_psc_2775
crossref_primary_10_1007_BF01212725
crossref_primary_10_1021_jo102371q
crossref_primary_10_1248_cpb_c17_00098
crossref_primary_10_1107_S1600536808016796
crossref_primary_10_1517_13543784_2011_574611
crossref_primary_10_2174_0929867325666180104153848
crossref_primary_10_3390_ijms20184421
crossref_primary_10_3109_07357909109039878
crossref_primary_10_1007_s11705_008_0023_2
crossref_primary_10_1210_er_2012_1014
crossref_primary_10_1073_pnas_96_20_11081
crossref_primary_10_1562_0031_8655_2001_074_0226_GOFRBE_2_0_CO_2
crossref_primary_10_3390_pharmaceutics13091433
crossref_primary_10_1107_S1600536808007228
crossref_primary_10_1016_j_brainresbull_2020_01_005
crossref_primary_10_1039_C2DT31782F
crossref_primary_10_3762_bjoc_14_64
ContentType Journal Article
Copyright 1991 INIST-CNRS
Copyright_xml – notice: 1991 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
OTOTI
5PM
DOI 10.1073/pnas.86.16.6313
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
OSTI.GOV
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
CrossRef

MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
EISSN 1091-6490
EndPage 6317
ExternalDocumentID PMC297829
7191552
2548206
19510858
10_1073_pnas_86_16_6313
86_16_6313
34318
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, U.S. Gov't, P.H.S
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA40003
– fundername: NCI NIH HHS
  grantid: CA40004
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
123
29P
2AX
2FS
2WC
3O-
4.4
53G
5RE
5VS
85S
AACGO
AAFWJ
AANCE
ABBHK
ABOCM
ABPLY
ABPPZ
ABTLG
ABXSQ
ABZEH
ACGOD
ACHIC
ACIWK
ACNCT
ACPRK
ADQXQ
ADULT
ADXHL
AENEX
AEUPB
AEXZC
AFFNX
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AQVQM
AS~
CS3
D0L
DCCCD
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HGD
HH5
HQ3
HTVGU
HYE
IPSME
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
KQ8
L7B
LU7
MVM
N9A
NEJ
N~3
O9-
OK1
P-O
PNE
PQQKQ
R.V
RHI
RNA
RNS
RPM
RXW
SA0
SJN
TN5
UKR
VOH
W8F
WH7
WHG
WOQ
WOW
X7M
XSW
Y6R
ZCA
ZCG
~02
~KM
-
02
08R
0R
1AW
55
AAPBV
ABFLS
ABPTK
ADACO
ADZLD
AFDAS
AJYGW
AS
ASUFR
DNJUQ
DOOOF
DWIUU
DZ
F20
GJ
JSODD
KM
OHM
PQEST
RHF
VQA
X
XFK
XHC
ZA5
692
6TJ
79B
AAYJJ
AAYXX
ACKIV
AFHIN
AFQQW
BKOMP
CITATION
NHB
TAE
YBH
YKV
YSK
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
YIF
YIN
7X8
OTOTI
5PM
ID FETCH-LOGICAL-c518t-d3396cea625f14e5a9e3f186b961c94e743e13e86e491ae7f7ff254170d924a03
ISSN 0027-8424
IngestDate Thu Aug 21 18:24:32 EDT 2025
Thu May 18 18:19:33 EDT 2023
Fri Jul 11 04:31:14 EDT 2025
Wed Feb 19 02:35:25 EST 2025
Wed Apr 02 07:17:28 EDT 2025
Tue Jul 01 01:21:54 EDT 2025
Thu Apr 24 23:02:07 EDT 2025
Wed Nov 11 00:30:01 EST 2020
Thu May 30 08:50:26 EDT 2019
Thu May 29 08:42:33 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Keywords Antineoplastic agent
Human
Hypothalamic hormone
Analog
Animal
Gonadotropin RH
Affinity
Drug targeting
Tumor cell
Metal Complexes
Platinum II Complexes
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c518t-d3396cea625f14e5a9e3f186b961c94e743e13e86e491ae7f7ff254170d924a03
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/297829
PMID 2548206
PQID 79151093
PQPubID 23479
PageCount 5
ParticipantIDs jstor_primary_34318
crossref_primary_10_1073_pnas_86_16_6313
pnas_primary_86_16_6313
pubmedcentral_primary_oai_pubmedcentral_nih_gov_297829
crossref_citationtrail_10_1073_pnas_86_16_6313
pnas_primary_86_16_6313_fulltext
pascalfrancis_primary_19510858
proquest_miscellaneous_79151093
pubmed_primary_2548206
osti_scitechconnect_7191552
ProviderPackageCode RNA
PNE
CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1989-08-01
PublicationDateYYYYMMDD 1989-08-01
PublicationDate_xml – month: 08
  year: 1989
  text: 1989-08-01
  day: 01
PublicationDecade 1980
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
PublicationTitle Proceedings of the National Academy of Sciences - PNAS
PublicationTitleAlternate Proc Natl Acad Sci U S A
PublicationYear 1989
Publisher National Academy of Sciences of the United States of America
National Acad Sciences
Publisher_xml – name: National Academy of Sciences of the United States of America
– name: National Acad Sciences
SSID ssj0009580
Score 1.5632154
Snippet Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and trans-bis(salicylaldoximato)copper(II) were incorporated...
Metal complexes related to the cytotoxic complexes cisplatin [cis-diamminedichloroplatinum(II)] and transbis(salicylaldoximato)copper(II) were incorporated...
Metal complexes related to the cytotoxic complexes cisplatin (cis-diamminedichloroplatinum(II)) and transbis(salicylaldoximato)copper(II) were incorporated...
SourceID pubmedcentral
osti
proquest
pubmed
pascalfrancis
crossref
pnas
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6313
SubjectTerms 550201 - Biochemistry- Tracer Techniques
Agonists
Amino Acid Sequence
AMINO ACIDS
ANIMAL CELLS
Animals
Antineoplastic agents
BASIC BIOLOGICAL SCIENCES
BETA DECAY RADIOISOTOPES
Biological and medical sciences
BODY
Breast cancer
Breast Neoplasms - metabolism
CARBOXYLIC ACIDS
Cell growth
Cell Membrane - metabolism
Cell membranes
CHEMICAL REACTIONS
CHROMATOGRAPHY
Chromatography, High Pressure Liquid
Cisplatin - analogs & derivatives
Cisplatin - chemical synthesis
Cisplatin - pharmacology
Copper - pharmacology
CROSS-LINKING
DAYS LIVING RADIOISOTOPES
Diamino amino acids
Dipeptides - chemical synthesis
ELECTRON CAPTURE RADIOISOTOPES
Female
General aspects
GLANDS
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - chemical synthesis
Gonadotropin-Releasing Hormone - metabolism
Gonadotropin-Releasing Hormone - pharmacology
GONADOTROPINS
HORMONES
Humans
In Vitro Techniques
INTERMEDIATE MASS NUCLEI
IODINE 125
IODINE ISOTOPES
ISOTOPES
LH
LIBERINS
LIQUID COLUMN CHROMATOGRAPHY
Luteinization
Luteinizing Hormone - metabolism
LYSINE
MAMMARY GLANDS
Medical sciences
MEMBRANE PROTEINS
METALLOPROTEINS
Molecular Sequence Data
MOLECULAR STRUCTURE
Nickel
NUCLEI
ODD-EVEN NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
Organometallic Compounds - chemical synthesis
Organometallic Compounds - pharmacology
ORGANS
Ovulation - drug effects
PEPTIDE HORMONES
Pharmacology. Drug treatments
Pituitary Gland - drug effects
Pituitary Gland - metabolism
PITUITARY HORMONES
PLATINUM COMPOUNDS
POLYMERIZATION
PROTEINS
RADIOISOTOPES
Rats
RECEPTORS
Receptors, LHRH - metabolism
SEPARATION PROCESSES
Structure-Activity Relationship
TRANSITION ELEMENT COMPOUNDS
Tumor cell line
TUMOR CELLS
Tumors
Title Highly Potent Metallopeptide Analogues of Luteinizing Hormone-Releasing Hormone
URI https://www.jstor.org/stable/34318
http://www.pnas.org/content/86/16/6313.abstract
https://www.ncbi.nlm.nih.gov/pubmed/2548206
https://www.proquest.com/docview/79151093
https://www.osti.gov/biblio/7191552
https://pubmed.ncbi.nlm.nih.gov/PMC297829
Volume 86
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgCGkvExsMwmDkgYehKaVuHMd5HAhUTVD2sEl7i1zH1gosqZb0pX89d7Hz1a0S8BJFdmJHvsv57vy7O0LeUy1g2wizYE6FCphhJpAyC4Ox0NpIoURU5y34PuPTK3Z-HV13cNs6uqSaj9T6wbiS_6EqtAFdMUr2HyjbDgoNcA_0hStQGK5_RWMEaaB3oqjwRP9WV3iKvkScSoanAtYvU2M14Cv0Il-s0TFwA2pqkesAy6XIstfSV1Qv2o2tbGAEs8ZveNZFoTjRUJ4GpxezXk1j-XNVrgee1XP4Huun7WDZsEj5ypZj746nPhW_SstH3zqXhMVcicYl0YQIwNbHbHB0I2ZdxmvHTn2hyUMbjnpPmoP4wRLEuSxHgo8oH20-CeRY3tbEBTsXM9F3u1qLNXQ9j8mTCVgSNfZz2s_LLGyUkvviJvtTHH7cmHeXPHVDDVQYi2KFDb0AkYzIWlnCz2VsVRTMmAujPGS9bIJwe1rN5TOy58wR_8zy1j55pPMDst9Q1T9xWck_PCc_LLP5ltn8IbP5LbP5hfF7zObfY7am5QW5-vrl8vM0cNU4AhVRUQVZGCZcaQkGs6FMRzLRoaGCzxNOVcI0qKKahlpwzRIqdWxiY2DBaDzOwMaX4_CQ7OQw_CviKyoyPWF8EhvGuKSSZSwaa0w-KMdKJR4ZNQucKpeqHium_E5ryEQcpriqqeAp5SnSxiMn7QtLm6Vl-6MHNcXa50JQoYVHjpB-KaidmDtZIchMVWlMsXzCxCPHA7J2c6B9IiJ4_WU9TdPen87f0pMah-7yyLuGO1KQ7XhgJ3NdrMo0htkx3ZtHDi2vtMM4TvQIHzBR249J44c9-eKmTh4_ScAmSF5vG_GI7HZ_9BuyU92t9FtQu6v5cf3j_AFwvtgn
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Highly+potent+metallopeptide+analogues+of+luteinizing+hormone-releasing+hormone&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Bajusz%2C+S&rft.au=Janaky%2C+T&rft.au=Csernus%2C+V+J&rft.au=Bokser%2C+L&rft.date=1989-08-01&rft.issn=0027-8424&rft.volume=86&rft.issue=16&rft.spage=6313&rft_id=info:doi/10.1073%2Fpnas.86.16.6313&rft_id=info%3Apmid%2F2548206&rft.externalDocID=2548206
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F16.cover.gif
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.pnas.org%2Fcontent%2F86%2F16.cover.gif